First dose of ETC-159 administered in Phase 1B of clinical trials, advancing the development of this drug to treat solid
More
Anticipated to surpass the US$ 20 Billion mark in 2019, generic oncology drugs will witness an increased demand in the
More
Post world war two, the UK had the difficult task ahead of rebuilding cities decimated during the blitz. Asbestos was
More
NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the local treatment of cancer,
More